IMCAS Academy

Introduction
Program
Speakers
Sponsor list
Accreditation

GO BACK

IMCAS World Congress 2022
Program

Adapt the schedule of the livestreamed class/congress to your time zone

Time zone reference: (UTC+02:00) Europe, Paris

Time zone

Time zone:Change time zone

If you are logged in, change your default time zone in your account

FOCUS ON S146

Young Dermatologist Awards

Room: Room 141 - Level 1
Date: Sunday 5 June 2022 at 10:30 to 11:30
Format: CONTEST > competition in front of a high-profile jury to present and pitch groundbreaking projects and/or research

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
10:30	Dr Michael BENZAQUEN	Jury		111713
10:30	Prof Marie BEYLOT BARRY	Jury		111709
10:30	Dr Magali DUBOIS	Jury		111712
10:30	Dr Meelad HABIB	Jury		111714
10:30	Prof Merete HAEDERSDAL	Jury		111710
10:30		Introduction of the Jury members		112635
10:33	Dr Claire DURETZ	YOUNG DERM AWARDS - Treatment of keloids by intralesional infiltrations of bleomycin: long-term follow-up	View	114928
10:41	Dr Sami SALAHIA	YOUNG DERM AWARDS - Comparative efficacy of lasers for the treatment of acne vulgaris: a systematic review and network meta-analysis	View	112626
10:49	Dr Gabriela GROVE	YOUNG DERM AWARDS - Impact of microwave-thermolysis energy levels on patient-reported outcome measures for axillary hyperhidrosis and osmidrosis	View	112628
10:57	Dr Manon DUBOIS	YOUNG DERM AWARDS - Real-life evaluation of the treatment of actinic keratoses by textile photodynamic therapy	View	112629
11:05	Dr Vinzent Kevin ORTNER	YOUNG DERM AWARDS - Laser-assisted topical treatment of nail disease: a pilot study and review of the literature	View	112641
11:13	Dr Morteza JAFARI	YOUNG DERM AWARDS: Skin hyperpigmentation index: a new objective method for automated quantification of skin hyperpigmentation	View	116755
11:21		Q&A and announcement of the winner		112632

Go to previous session

Go to next session

Recommended sessions

Skin lesions

Dermoscopy & medical imaging

Pigmentation

Arms (non-surgical)

Hyperhidrosis

Dr Michael BENZAQUEN

Dermatologist

Switzerland

Other author(s) :

Jury

Prof Marie BEYLOT BARRY

Dermatologist

France

Other author(s) :

Jury

Dr Magali DUBOIS

Dermatologist

France

Other author(s) :

Jury

Dr Meelad HABIB

Dermatologist

Netherlands

Other author(s) :

Jury

Prof Merete HAEDERSDAL

Dermatologist

Denmark

Other author(s) :

Jury

Introduction of the Jury members

Dr Claire DURETZ

France

Other author(s) :

YOUNG DERM AWARDS - Treatment of keloids by intralesional infiltrations of bleomycin: long-term follow-up

Objectives: The objective of this study was to evaluate the immediate (3 months) and long-term (24 months) efficacy of intralesional bleomycin injections (BIL) for the treatment of keloids and to estimate their tolerance.

Introduction: Keloids are a pathological healing process usually occurring after skin trauma, sometimes minor. Despite their benign nature, keloids can have significant repercussions on the quality of life of patients. The treatments vary in effectiveness and are rarely satisfactory. The literature is poor in therapeutic trials or retrospective series.
Bleomycin is a chemotherapeutic agent in the family of cytotoxic antibiotics.The few published studies to assess the efficacy and safety of bleomycin in keloids involved small samples of patients followed on short periods.

Materials / method: This retrospective, monocentric study (CHU of Reims), was conducted from January 2008 to December 2015, included all patients with keloid treated with BIL, with a minimum follow-up of 3 months after the last injection. Injections were performed by the same operator (10mL bleomycin ; concentration 1.5 IU/mL). The number of injections was adapted to the clinical response. Main outcome was the reduction of keloid size classified as: complete (100%), partial major (75% -100%), partial minor (50% -75%) and insufficient (<50%).

Results: Among 70 patients, 66 have been analyzed. This treatment required an average of 3.4 ± 1.3 injections per keloid. The efficacy of a 3 months-lasting treatment, evaluated among 57 patients, was greater than 75% for two thirds of the patients and completed for 40% of them. At 24 months, the evaluation was concerning 44 patients, 52% of them had a keloid decrease of more than 75% and for 30% of them, the recession was complete. Nine recurrences were observed among 50 patients (recurrence rate of 18%) over a follow-up period of 24.8 ± 10.5 months. No systemic complications have been occured.

Conclusion: Our study shows the short-term and long-term efficacy and safety of BIL in the treatment of keloids.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Sami SALAHIA

Egypt

Other author(s) :

YOUNG DERM AWARDS - Comparative efficacy of lasers for the treatment of acne vulgaris: a systematic review and network meta-analysis

Objectives: 1: Comparing laser devices and its application on Acne Vulgaris.
2: Evaluate and Rank the various Lasers to assess the best therapy for Acne Vulgaris

Introduction: Acne is one of the most common disorders encountered in everyday practice. Lasers in particular have a central role in the management of acne, which tends to be refractory to medical therapies, while there is a controversy about which of laser is effective compared to others. Therefore, we aimed to evaluate and rank the various therapies through this network meta-analysis of clinical studies.

Materials / method: We searched on PubMed, Scopus, and Cochrane Central Register of Controlled Trials until June 2021, to include randomized controlled trials for acne vulgaris that compared lasers. A random-effect model of network meta-analysis with frequentist framework was performed for all treatments compared to Control. Mean differences (MDs) of lesions count with 95% confidence interval were calculated, and all interventions were ranked by the Surface Under the Cumulative Ranking (SUCRA) values.

Results: 18 RCTs were enrolled to assess the reduction of inflammatory and non-inflammatory lesion counts. Ranking probability showed that Erbium Glass Laser (SUCRA score= 0.90) and PDT+MAL (SUCRA score= 0.68) were significantly superior to control. Erbium Glass Laser was superior in treating inflammatory acne lesions compared to other lasers such as PDL and PDT+ALA. On the other hand, Erbium Glass Laser (SUCRA = 0.74), and PDT+ ALA (SUCRA score = 0.71) were significantly superior to control in reducing non-inflammatory lesions, while no significant differences were observed among other interventions.

Conclusion: This network meta-analysis demonstrated that lasers could be a good alternative treatment for those who were diagnosed with acne vulgaris. Erbium Glass laser and Photodynamic therapy showed a high probability of being effective for acne vulgaris.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Gabriela GROVE

Dermatologist

Denmark

Other author(s) :

YOUNG DERM AWARDS - Impact of microwave-thermolysis energy levels on patient-reported outcome measures for axillary hyperhidrosis and osmidrosis

Objectives: • Acquire knowledge on differences between energy levels of microwave-thermolysis device
• Understand the impact of patient-reported outcomes on patient satisfaction following microwave-thermolysis
• Support clinical decision-making for future treatment with microwave-thermolysis

Introduction: Microwave-thermolysis (MWT) is an emerging treatment for axillary hyperhidrosis reducing both sweat and odor. No prior studies have investigated and compared the different energy settings of the available MWT-device. This study evaluates patient-reported outcomes measures (PROMs) for axillary hyperhidrosis and osmidrosis following MWT-treatment at two different energy levels.

Materials / method: Twenty adults with axillary hyperhidrosis and osmidrosis reported sweat on Hyperhidrosis Disease Severity Scale (HDSS: 1-4) and odor on Odor Scale (OS: 1-10), respectively, supplemented by overall Dermatologic Life Quality Index (DLQI: 0-30). This was a prospective, randomized, patient-blinded and intra-individually controlled study with three months follow-up (FU). Randomization comprised MWT-treatment of one axilla with the standard medium energy setting (energy level 3) and the contralateral axilla with the standard high energy setting (energy level 5).

Results: At baseline, patients reported substantial sweat and odor, negatively affecting patients’ quality of life.
At 3-month FU, PROMs showed improved quality of life with significantly reduced sweat and odor. Overall DLQI was reduced from median 10 to 4, with a median reduction of 6.5 points (p=0.0002). HDSS was reduced from median 4 to 2 for both energy level 3 and 5, with a median reduction of 1 and 2 points, respectively (p=0.014). OS was reduced from median 8 to 3 for both energy levels with median reduction of 3.5 and 4 points for energy level 3 and 5, respectively (p=0.017).

Conclusion: Microwave-thermolysis effectively improved axillary sweat and odor three months after baseline. Correspondingly, patients’ quality of life improved significantly. Treatment with energy level 5 presented a subtle, but significant increase of efficacy based on PROMs for both sweat and odor reduction.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: miraDry Inc: Equipment

Dr Manon DUBOIS

Dermatologist

France

Other author(s) :

YOUNG DERM AWARDS - Real-life evaluation of the treatment of actinic keratoses by textile photodynamic therapy

Objectives: - Evaluate the efficacy of the first textile PDT device, in the treatment of actinic keratosis, in comparison to conventional PDT
- Evaluate the tolerance of the textile PDT treatment, and the satisfaction of the patients

Introduction: Actinic keratoses (AK) are a common precancerous skin condition in dermatology practice. Photodynamic therapy (PDT) with ALA or MAL is an effective but painful treatment of fields of cancerization particularly when conventional illumination sources and irradiation rates are used. Two prior studies showed that illumination with textile PDT was not inferior to conventional PDT but induced less pain. A first medical device has recently been marketed with textile based lighting. We performed a real-life study to evaluate efficacy and tolerance of this device.

Materials / method: We carried out a single-center retrospective study. We collected data from patients treated with textile PDT with MAL for AKs localized on scalp and temples between November 2018 and November 2019. The primary endpoint was complete clearance rate (CR) at 3 months-follow up.

Results: Data of 39 patients were reviewed in the study, with a total of 417 AKs. The CR rate was 72.6 % (95 %CI 67.9-77.0) at 3 months-follow up and 67.5 % (95 %CI 61.2-73.3) at 6 months-follow up. The median pain felt during the session was 0 and there wasn't erythema after the session for 64.1 %.

Conclusion: Our real-life study confirms efficacy and safety of textile PDT device in the treatment of scalp and temples AKs, with excellent tolerance and minimal pain reported.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Vinzent Kevin ORTNER

Denmark

Other author(s) :

YOUNG DERM AWARDS - Laser-assisted topical treatment of nail disease: a pilot study and review of the literature

Objectives: • Become familiar with what the literature says about laser-assisted drug delivery in nail tissue
• Understand the risks and benefits of laser pretreatment in the topical management of nail disease
• Learn from our early-adopter experience with laser-assisted topical treatment of nail psoriasis

Introduction: Ablative fractional laser (AFL) pretreatment for topical therapy of nail disease is gaining ground. To investigate the safety and efficacy of this drug-device treatment approach, we conducted a randomized intra-patient controlled trial on laser-assisted Calcipotriol/Betamethasone Dipropionate (Cal/BD) foam treatment for psoriatic nail disease (PND) and provided an overview of the pertinent literature.

Materials / method: We included 11 patients with 144 psoriatic nails with an average NAPSI score (0-130) of 80. Half of each patient’s nails were randomized to receive AFL at baseline, week 6, and week 12. Patients were instructed to apply Cal/BD foam once daily for 24 weeks. Treatment response was monitored clinically supported with patient-reported outcome measures, optical coherence tomography (OCT), and patient-obtained photographs using a smartphone app.

For the systematic literature review, two investigators searched Pubmed for clinical trials on laser-assisted topical treatment of nail disease.

Results: Cal/BD achieved a reduction in NAPSI -68% (p=0.001), 60% decrease in quality of life burden, and a 43% reduction in OCT-assessed PND. AFL pretreatment achieved higher clinical (NAPSI -78%) and OCT-assessed (-46%) improvement than Cal/BD alone (NAPSI -58%, OCT -37%) but with no significant difference. Smartphone app images documented paronychia (n=1) and mild local skin reactions.

We identified 21 articles on AFL pretreatment for onychodystrophy (n=1), PND (n=3), and onychomycosis (n=17). The majority of studies (90.5%) concluded that AFL pretreatment is safe and effective.

Conclusion: While Cal/BD foam treatment substantially improved PND both with and without AFL, the available literature suggests that laser pretreatment could be a clinically relevant enhancement strategy for various types of topical therapies. Future studies on the impact of laser settings and choice of formulation may help optimize the efficacy of laser-assisted topical treatment of nail disease.

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): LEO Pharma

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: LEO Pharma

Dr Morteza JAFARI

Dermatologist

Switzerland

Other author(s) :

YOUNG DERM AWARDS: Skin hyperpigmentation index: a new objective method for automated quantification of skin hyperpigmentation

Objectives: To establish an unbiased, and fully-automated method of quantitively evaluating and documenting skin hyperpigmentation.

Introduction: Measurement of skin hyperpigmentation is clinically important in the assessment, follow up, and therapy of hyperpigmented lesions. To date, there are no reliable objective methods for measuring skin hyperpigmentation quantitatively. Here, we report a novel, practical, unbiased, and fully-automated method of quantitively evaluating and documenting skin hyperpigmentation, the “skin hyperpigmentation index” (SHI) .

Materials / method: The SHI is a program with a deconvolution of color and an image histogram profiling of brown pixel intensities for the automated evaluation of quantitative skin pigmentation. The SHI defines the ratio of two scores, namely hyperpigmented skin of the affected area and normal sun protected skin from the same patient.

Results: This results in a range from 1 (no pigmentation) to 4 (maximum pigmentation). For a practical evaluation of the score, a free SHI-calculator can be used online, which is accessible to all practitioners (https://shi.skinimageanalysis.com/).

Conclusion: The SHI is a fully automated method for the quantitative assessment of skin pigmentation which can easily be applied to any skin type with any type of hyperpigmentation. This allows a simple, fast and standardized quantification of skin hyperpigmentation and is useful for monitoring the progress and planning of whitening therapy.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Q&A and announcement of the winner

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Americas
IMCAS Asia
IMCAS World Congress

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS World Congress 2022 Program

FOCUS ON S146

Young Dermatologist Awards

Lectures of the session

Recommended sessions

IMCAS World Congress 2022
Program